Camrelizumab Boosts Chemo for Early Triple-Negative Breast Cancer

JAMA Network

About The Study: Among patients with early or locally advanced triple-negative breast cancer, the addition of camrelizumab, an anti–PD-1 antibody, to neoadjuvant chemotherapy significantly improved pathological complete response.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.